Милдронат®

General characteristics. Structure:

Active ingredient: meldoniya dihydrate of 100 mg;

Excipient: water for injections.

Pharmacological properties:

Pharmacodynamics. Meldony (МИЛДРОНАТ®) - a structural analog of a gamma butyrobetaine – substance which is in each cell of a human body.

In the conditions of the raised loading МИЛДРОНАТ® recovers balance between delivery and the need of cells for oxygen, eliminates accumulation of toxic products of exchange in cells, protecting them from damage; exerts also tonic impact. As a result of its use the organism gains ability to maintain loading and to quickly recover power reserves. Thanks to these MILDRONAT® properties use for treatment of various disturbances of activity of cardiovascular system, blood supply of a brain, and also for increase in physical and intellectual effeciency. As a result of decrease in concentration of a carnitine the gamma butyrobetaine having vazodilatiruyushchy properties is strenuously synthesized. In case of acute ischemic injury of myocardium МИЛДРОНАТ® slows down formation of a necrotic zone, shortens the rehabilitation period. At heart failure increases contractility of a myocardium, increases tolerance to an exercise stress, reduces the frequency of attacks of stenocardia. At acute and chronic ischemic disorders of cerebral circulation МИЛДРОНАТ® improves blood circulation in the ischemia center, promotes redistribution of blood in favor of the ischemic site. Drug eliminates functional disturbances of a nervous system at patients with an alcoholism at an abstinence syndrome.

Pharmacokinetics. Bioavailability of drug after intravenous administration is equal to 100%. The maximum concentration in a blood plasma is reached right after its introduction. It is metabolized in an organism with formation of two main metabolites which are removed by kidneys. The elimination half-life (T1/2) makes 3-6 hours.

Indications to use:

In complex therapy of coronary heart disease (stenocardia, a myocardial infarction); chronic heart failure and a dishormonal cardiomyopathy, and also in complex therapy of acute and chronic disorders of blood supply of a brain (a stroke and cerebrovascular insufficiency).
Hemophthalmia and retinal apoplexies of various etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (diabetic, hypertensive).
Reduced working capacity; intellectual and physical overworks (including at athletes).
Abstinence syndrome at an alcoholism (in a combination with specific therapy of alcoholism).

Route of administration and doses:

In view of possible development of exciting effect it is recommended to apply in the first half of day.

1. Cardiovascular diseases
As a part of complex therapy on 0,5-1 g a day intravenously (5-10 ml of solution for parabulbar and intravenous administration of 100 mg/ml), applying all dose at once or to divide into 2 times. A course of treatment – 4-6 weeks.

2. Disturbance of cerebral circulation
Acute phase – on 0,5 g once a day intravenously within 10 days, passing to intake. The general course of treatment – 4-6 weeks.
Repeated courses (usually 2-3 times a year) are possible after consultation with the doctor.

3. Oftalmopatologiya (hemophthalmia and retinal apoplexies of various etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (diabetic, hypertensive))
Parabulbarno on 0,5 ml of solution for parabulbar and intravenous administration of 100 mg/ml within 10 days. Including it is applied as a part of a combination therapy.

4. Intellectual and physical overworks
The adult on 0,5 g intravenously once a day. A course of treatment – 10-14 days. If necessary treatment is repeated in 2-3 weeks.

5. Alcoholism
Intravenously on 0,5 g 2 times a day. A course of treatment – 7-10 days.

Features of use:

Long-term experience of treatment of an acute myocardial infarction and unstable stenocardia in cardiological departments shows what МИЛДРОНАТ® is not row drug I at an acute coronary syndrome and its use is not sharply necessary.

There are no data on an adverse effect of the drug MILDRONAT® on the speed of psychomotor reaction.

Side effects:

Seldom - allergic reactions (reddening, rashes, an itch, hypostasis), and also the dispeptic phenomena, tachycardia, decrease or increase in arterial pressure, excitement.
Very seldom – an eosinophilia, the general weakness.

Interaction with other medicines:

It is possible to combine with anti-anginal means, anticoagulants, antiagreganta-m, antiarrhytmic means, diuretics, bronchial spasmolytics.

Strengthens effect of cardiac glycosides.

In view of possible development of moderate tachycardia and arterial hypotension, it is necessary to be careful at a combination with nitroglycerine, nifedipine, alpha adrenoblockers, other antihypertensives and peripheral vazodilatator as МИЛДРОНАТ® strengthens their action.

Contraindications:

Hypersensitivity to drug components, increase in intracranial pressure (at disturbance of venous outflow, intracranial tumors), age up to 18 years (efficiency and safety are not established), pregnancy, the feeding period a breast.

With care:
At diseases of a liver and/or kidneys.

Overdose:

Symptoms: the lowering of arterial pressure which is followed by a headache, tachycardia, dizziness and the general weakness.
Treatment: symptomatic.
МИЛДРОНАТ® малотоксичен also does not cause side effects, patients hazardous to health.

Storage conditions:

To store at a temperature not above 25 °C.
Not to freeze!
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Solution for parabulbar and intravenous administration of 100 mg/ml (ampoule) of 5 ml.
On 5 ampoules in a strip packaging from a polyvinyl chloride film or from a polietilentereftalatny film without covering.
On 2 strip packagings together with the application instruction in a pack from a cardboard.